Skip to main content Skip to main navigation menu Skip to site footer

Platinum based chemotherapy for Ovarian Carcinoma

  • Ardhanu Kusumanto ,

Abstract

Background: The management of advanced epithelial ovarian cancer (EOC) has evolved to become a combination of initial cytoreductive surgery (CRS) followed by chemotherapy. Chemotherapy has been regarded as standard therapy for the majority of women with advanced EOC for several decades. A thorough understanding of drug resistance mechanisms is needed, as this remains the largest obstacle in treating patients with recurrent disease. The aim of characterized by age of women, type, stage, grade and clinical staging of the tumor.

Methods: Data from regimens containing platinum (cisplatin or carboplatin) used in treating ovarian carcinoma in Sarjito General Hospital were analyzed prospectively. Relative dose intensity was calculated as a fraction of the dosage of a drug in the standard regimen of cyclophosphamide, doxorubicin, and platinum.

Results:   The higher age of women will have lower response to chemotherapy. Women aged below 50 years old are much higher responsive to chemotherapy.

Conclusion: Cisplatin based chemotherapy has a better response to ovarian carcinoma in earlier stage. In higher stage, it will give a complete removal of all macroscopic tumor tissue.

References

  1. Garcia M, Jemal A, Ward EM, Center MM, Hao Y, Siegel RL, Thun MJ. Global Cancer Facts & Figures 2007. Atlanta, GA: American Cancer Society, 2007.
  2. Sumanasekera W, Beckmann T, Fuller L, Castle M, Huff M. Epidemiology of Ovarian Cancer: Risk Factors and Prevention, Biomed J Sci & Tech Res, 2018.
  3. Michael G, Teneriello MD, Robert C, Park MD. Early Detection of Ovarian Cancer. CA Cancer J Clin 1995;45:71-87.
  4. Torpy JM, Burke AE, Golub RM. Chemoteraphy. JAMA. 2011;305(23):2484.
  5. Morice P, Gouy S, Leary A. Mucinous Ovarian Carcinoma. N Engl J Med. 2019, 380:1256-1266.
  6. Karst AM, Drapkin R. Ovarian cancer pathogenesis: a model in Evolution. J. Oncol . 2010. 1687-8450:932371.
  7. Helm WC, States JC. Enhancing the efficacy of cisplatin in ovarian cancer treatment could arsenic have a role, J Ovarian Res. 2009.
  8. McGuire WP III, Markman M. Primary ovarian cancer chemotherapy: current standards of care, British Journal of Cancer. 2003. 89 (3): 3-8.
  9. Vasey PA. Resistance to chemotherapy in advanced ovarian cancer: mechanisms and current strategies British Journal of Cancer. 2003. 89 (3): 23 – 28.

How to Cite

Kusumanto, A. (2020). Platinum based chemotherapy for Ovarian Carcinoma. Bali Medical Journal, 9(1), 404–407. https://doi.org/10.15562/bmj.v9i1.1686

HTML
0

Total
0

Share

Search Panel

Ardhanu Kusumanto
Google Scholar
Pubmed
BMJ Journal